Expertise in
6
conditions

Dr. Jonathan Bernstein

Hematology | Oncology
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 
Expertise in
6
conditions
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 

Overview

Jonathan Bernstein is a Hematologist and an Oncologist in Hershey, Pennsylvania. Dr. Bernstein is highly rated in 6 conditions, according to our data. His top areas of expertise are Chronic Spontaneous Urticaria (CSU), Hemophilia A, Mast Cell Activation Syndrome (MCAS), and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

His clinical research consists of co-authoring 665 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

The Milton S. Hershey Medical Center
500 University Dr, Hershey, PA 17033

Additional Areas of Focus

Dr. Bernstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2024
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: Dupilumab
Study Phase: Phase 4
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Biological
Study Phase: Phase 4
View 9 Less Clinical Trials

653 Total Publications

Genetic Variants in Recurrent Euploid Pregnancy Loss.
Genetic Variants in Recurrent Euploid Pregnancy Loss.
Journal: medRxiv : the preprint server for health sciences
Published: November 19, 2025
Similar Doctors
Nelson Yee
Expertise in
21
conditions
Dr. Nelson Yee
Hematology | Oncology
Expertise in
21
conditions
Dr. Nelson Yee
Hematology | Oncology

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.2 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nelson Yee is a Hematologist and an Oncologist in Hershey, Pennsylvania. Dr. Yee is highly rated in 21 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Bone Marrow Aspiration.

Expertise in
3
conditions
Dr. Sinisa Dovat
Hematology | Oncology
Expertise in
3
conditions
Dr. Sinisa Dovat
Hematology | Oncology

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.2 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Sinisa Dovat is a Hematologist and an Oncologist in Hershey, Pennsylvania. Dr. Dovat is highly rated in 3 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Embryonal Tumor with Multilayered Rosettes.

Expertise in
24
conditions
Dr. Seema Naik
Hematology | Oncology
Expertise in
24
conditions
Dr. Seema Naik
Hematology | Oncology

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.2 miles away)
717-531-8401
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Seema Naik is a Hematologist and an Oncologist in Hershey, Pennsylvania. Dr. Naik is highly rated in 24 conditions, according to our data. Her top areas of expertise are Burkitt Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jonathan Bernstein

How do I make an appointment with Dr. Jonathan Bernstein?

You can book an appointment with Dr. Jonathan Bernstein by calling their office at 800-243-1455. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Bernstein a top-rated expert for Chronic Spontaneous Urticaria (CSU)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Bernstein is classified as an Elite expert for Chronic Spontaneous Urticaria (CSU), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Bernstein specialize in?

While Dr. Jonathan Bernstein is a Hematology, they have specific expertise in Chronic Spontaneous Urticaria (CSU), Hemophilia A, and Mast Cell Activation Syndrome (MCAS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jonathan Bernstein participate in research or clinical trials?

Yes. Dr. Jonathan Bernstein has published 653 articles and abstracts on conditions like Chronic Spontaneous Urticaria (CSU). You can view a list of Dr. Jonathan Bernstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Bernstein accept my insurance?

Dr. Jonathan Bernstein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-243-1455 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile